Kelun Biotech gets PD-1 NMPA approval for nasopharyngeal cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced to have received marketing authorization in China from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed tagitanlimab (KL-A167) used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). - PR Newswire

Astellas Pharma Inc. will book an impairment loss for intangible assets of approximately 116 billion yen related to IZERVAY as other expenses. — Press Release

India’s Ministry of Health is going to hold series meetings with Pharma executives about drug quality. Amid recent recalls and quality issues reports, the regulator is discussing ways with the industry to address the concern. - Economic Times